skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent

Review

(2957) Views  (1473) Full article downloads

Authors: Mark Welliver, John McDonough, Nicholas Kalynych, Robert Redfern

Published Date February 2008 Volume 2008:2 Pages 49 - 59
DOI: http://dx.doi.org/10.2147/DDDT.S2757

Mark Welliver1,3, John McDonough1,3, Nicholas Kalynych1,2,3, Robert Redfern3

1University of North Florida, Nurse Anesthetist Program, Jacksonville, Florida, USA; 2Shands Jacksonville, Perioperative Services, Jacksonville, Florida, USA; 3University of Florida, Department of Anesthesiology, Jacksonville, Florida, USA

Abstract: Neuromuscular blockade, induced by neuromuscular blocking agents, has allowed prescribed immobility, improved surgical exposure, optimal airway management conditions, and facilitated mechanical ventilation. However, termination of the effects of neuromuscular blocking agents has, until now, remained limited. A novel cyclodextrin encapsulation process offers improved termination of the paralytic effects of aminosteroidal non-depolarizing neuromuscular blocking agents. Sugammadex sodium is the first in a new class of drug called selective relaxant binding agents. Currently, in clinical trials, sugammadex, a modified gamma cyclodextrin, has shown consistent and rapid termination of neuromuscular blockade with few side effects. The pharmacology of cyclodextrins in general and sugammadex in particular, together with the results of current clinical research are reviewed. The ability of sugammadex to terminate the action of neuromuscular blocking agents by direct encapsulation is compared to the indirect competitive antagonism of their effects by cholinesterase inhibitors. Also discussed are the clinical implications that extend beyond fast, effective reversal, including numerous potential peri-operative benefits.

Keywords: modified cyclodextrin, selective relaxant binding agent (SRBA), sugammadex, encapsulation, muscle relaxants, neuromuscular blockade reversal








Readers of this article also read:

Selective reversal of muscle relaxation in general anesthesia: focus on sugammadex
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
New formulation of an old drug in hypertension treatment: the sustained release of captopril from cyclodextrin nanoparticles
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Preparation and evaluation of lidocaine hydrochloride in cyclodextrin inclusion complexes for development of stable gel in association with chlorhexidine gluconate for urogenital use
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Preparation and evaluation of antimicrobial activity of nanosystems for the control of oral pathogens Streptococcus mutans and Candida albicans
Cyclodextrin-erythromycin complexes as a drug delivery device for orthopedic application
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University